CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (March 2021)

12 slides from CASI Pharmaceuticals's investor presentation, Mar 12, 2021

  1. Slide 1: Corporate Presentation March 2021

    Corporate Presentation March 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to

  3. Slide 3: CASI - Highlights

    CASI - Highlights • EVOMELA® launched in China − Strong growth in sales, with 2020 full-year projected revenue of $15 million* and project 50%+ growth in 2021 • Initiating regulatory submission and registration studies in China for Thiotepa in 2021 • CNCT19: CD19 CAR-T Cell Therapy − Granted Breakth

  4. Slide 4: CB-5339 VCP/P97 Inhibitor

    CB-5339 VCP/P97 Inhibitor Partner: Cleave Therapeutics 4

  5. Slide 5: CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97

    CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97 Novel target - VCP/p97 Lead Product - CB-5339 • VCP is a AAA ATPase enzyme that • A 2nd generation small molecule inhibitor of VCP/p97 extracts and unfolds proteins, with biochemical potency of 9 nM essential for cancer cell survival • A

  6. Slide 6: VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation

    VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation and Drives Cytotoxic Buildup of Proteins in the Endoplasmic Reticulum Endoplasmic Reticulum Endoplasmic Reticulum (ER) Lumen Association Degradation (ERAD) Target for Bortezomib and Aberrant protein synthesis Carfilzomib • Critical t

  7. Slide 7: Evolving Understanding - Unique Role for VCP/p97 in the DNA Damage Response

    Evolving Understanding - Unique Role for VCP/p97 in the DNA Damage Response (DDR) With Exquisite AML Sensitivity • DNA damaging agents, such as 7+3, are standard of care in AML – but patients develop resistance due to upregulation of DNA damage response proteins1 • VCP/p97 plays a key role in this r

  8. Slide 8: VCP/p97 is an Attractive Broad Oncology Target

    VCP/p97 is an Attractive Broad Oncology Target • Cleave’s agent, CB-5339, has impressive efficacy across a broad Cytotoxic Activity Across Broad Panels of Cancer Cell Lines panel of cancer cell lines with IC50s in the sub-100nM for the most sensitive lines 100 nM – 1 µM • Hematologic malignancies su

  9. Slide 9: Cleave CB-5339 Phase 1 Study Focused on AML/MDS

    Cleave CB-5339 Phase 1 Study Focused on AML/MDS Open to R/R AML/MDS and Myeloid Malignancies Monotherapy Dose Expansion Combination R/R AML at RP2D R/R AML at RP2D Accelerated Titration 3 + 3 Escalation Monotherapy Dose Expansion Combination Int./Higher Risk MDS Int./Higher Risk MDS • CB-5339 dosed

  10. Slide 10: Scientific Rationale for CB-5339 in Acute Myeloid Leukemia

    Scientific Rationale for CB-5339 in Acute Myeloid Leukemia • VCP/p97 has an emerging role in chromatin associated degradation and the DNA damage response (DDR) that can be leveraged to drive genomic stress and cytotoxicity in cancer. VCP CAD / DDR DNA Damage Cellular Genotoxic Stress Inhibition Disr

  11. Slide 11: Clinical Assets

    Clinical Assets U.S. FDA-Approved Products In-Licensed for Greater China Region In-Licensed CTA Filing & Review Phase 2 NDA Filing & Indication Registration Trial Review EVOMELA Multiple Myeloma Licensed and Commercially Available in China China Developed Innovative Cell Therapy with Co-Commercializ

  12. Slide 12: Thank You

    Thank You

CASI Pharmaceuticals — Investor Presentation (March 2021) on 6ix